IP Library Granted Patent US 10,712,282
Granted Patent B2
US 10,712,282 · App. 14/481,264 · Granted Jul 14, 2020

System and methods for analyte detection

Inventors: Elizabeth A. Holmes (Palo Alto, CA); Ian Gibbons (Newark, CA); Timothy M. Kemp (Palo Alto, CA); John Howard (Palo Alto, CA); Shaunak Roy (Palo Alto, CA)
Assignee: Labrador Diagnostics LLC
G01N21/76A61B5/1411A61B5/1427A61B5/14532A61B5/157A61B5/15142A61B5/412A61B5/417B01L3/50273G01N33/50G01N33/53G01N33/5302G01N33/54386G16H40/63A61B5/1495A61B5/14546A61B5/150022A61B5/150099A61B5/150251A61B5/150763A61B5/150854B01L2300/021B01L2300/023B01L2300/044B01L2300/0636B01L2300/087B01L2300/0816B01L2300/0867B01L2300/0877B01L2300/0883B01L2300/0887G01N2500/00Y02A90/26Y10T436/10Y10T436/11Y10T436/115831Y10T436/12Y10T436/143333
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,712,282
App. No.
14/481,264
Granted
Jul 14, 2020
Kind
B2
Abstract

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications.

Claims (43)

1. A method for detecting an analyte in a bodily fluid sample of a subject, comprising:

providing a cartridge comprising a sample collection unit and an assay assembly, the sample collection unit configured to receive the bodily fluid sample, and the assay assembly comprising a reaction site containing a dry reactant to be liquefied prior to completing an assay, the dry reactant configured to react with the analyte in the bodily fluid sample;

inserting the cartridge containing the bodily fluid sample into a reader assembly, the cartridge comprising an identifier corresponding to a protocol to be used with the cartridge, the protocol including instructions to perform the assay, wherein the reader assembly is configured to receive the cartridge inside the reader assembly;

receiving at the reader assembly a selected protocol from an external device, wherein the selected protocol is selected from a plurality of protocols in response to detecting the identifier of the cartridge;

executing the selected protocol to perform the assay such that an actuating element causes movement of the bodily fluid sample to the reaction site according to the selected protocol for reaction with the reactant contained within the reaction site, wherein the assay assembly yields a detectable signal generated from the analyte in the sample that indicates a concentration of the analyte;

detecting the detectable signal using a detector based on the selected protocol; and

transmitting an indication that the detectable signal was detected from the detector to the external device.

2. The method of claim 1 , wherein the reader assembly comprises a detection assembly configured to detect the detectable signal, and a communication assembly configured to transmit the indication that the detected signal was detected to the external device.

3. The method of claim 1 further comprising:

providing a second cartridge configured to receive a second bodily fluid sample from the same subject at a second time, the second cartridge being configured the same as the first cartridge and configured to perform the same assay;

inserting the second cartridge containing the second bodily fluid sample of the same subject into the reader assembly, the second cartridge further comprising an identifier corresponding to a protocol to be used with the second cartridge;

receiving at the reader assembly a second selected protocol from the external device, wherein the second selected protocol is selected in response to detecting the identifier of the second cartridge;

executing the second selected protocol such that the second cartridge's assay assembly yields a detectable signal generated from the analyte in the second sample that indicates a concentration of the analyte.

4. The method of claim 1 , wherein the selected protocol further comprises a detection method.

5. The method of claim 1 , wherein the selected protocol varies depending on the identifier of the cartridge that is recognizable by an identifier detector.

6. The method of claim 1 , wherein the reagent is an immunoassay reagent.

7. The method of claim 1 , wherein the analyte detected is selected from the group consisting of: a polypeptide, glycoprotein, polysaccharide, lipid, nucleic acid, and a combination thereof.

8. The method of claim 1 , wherein the analyte detected is selected from the group consisting of: drug, drug metabolite, biomarker indicative of a disease, tissue specific marker, and biomarker specific for a cell or cell type.

9. The method of claim 1 , wherein the analyte detected is a biomarker selected from said plurality of analytes listed in Table 4.

10. The method of claim 1 , wherein the reactant comprises a plurality of immunoassay reagents capable of reacting with a plurality of analytes.

11. The method of claim 1 , wherein the detectable signal is a luminescent signal.

12. The method of claim 1 , wherein the cartridge further comprises a microneedle configured to obtain the bodily fluid sample.

13. The method of claim 1 , wherein the concentration of the analyte is indicative of a pharmacokinetic or a pharmacodynamic parameter.

14. The method of claim 1 , wherein the bodily fluid sample comprises blood.

15. The method of claim 3 , wherein at least one pharmaceutical agent administered to said subject between when the first bodily fluid sample is obtained and the second bodily fluid sample is obtained is different from a pharmaceutical agent administered before the first bodily fluid sample is obtained.

16. The method of claim 1 , wherein the selected protocol effects dilution of said sample bringing the concentration of the analyte into a detectable range.

17. The method of claim 1 , wherein the selected protocol is selected based on the identifier and, depending on changes in a treatment regime, based on at least one comparison of the concentration of the analyte with stored pharmacological data according to a bioinformatic model at said external device.

18. The method of claim 1 , further comprising using an external server that stores mathematical algorithms to process a photon count from the reader assembly to calculate analyte concentration in the bodily fluid.

19. A method for detecting an analyte in a bodily fluid sample of a subject, comprising:

providing a fluidic device comprising a sample collection unit and an assay assembly, the sample collection unit configured to receive the bodily fluid sample, and the assay assembly comprising a reaction site containing a dry reactant to be contacted with liquid prior to completing an assay, the dry reactant configured to react with the analyte in the bodily fluid sample after being contacted with liquid;

inserting the fluidic device containing the bodily fluid sample into a reader assembly, the fluidic device comprising an identifier corresponding to a protocol to be used with the fluidic device, the protocol including instructions to perform the assay, wherein the reader assembly is configured to receive the fluidic device inside the reader assembly;

receiving at the reader assembly a selected protocol from an external device, wherein the selected protocol is selected from a plurality of protocols in response to detecting the identifier of the fluidic device;

executing the selected protocol to perform the assay such that an actuating element causes movement of the bodily fluid sample within the fluidic device to the reaction site according to the selected protocol for reaction with the reactant contained within the reaction site after the reactant is contacted with liquid, wherein the assay assembly yields a detectable signal generated from the analyte in the sample, indicating the presence of the analyte;

detecting the detectable signal using a detector; and

transmitting from the detector to the external device an indication that the detectable signal was detected.

20. A method of testing for an analyte in a bodily fluid sample of a subject, comprising:

providing a fluidic device comprising a sample collection unit and an assay assembly, the sample collection unit configured to receive the bodily fluid sample, and the assay assembly comprising a reaction site containing a dry reactant to be contacted with liquid prior to completing an assay, the dry reactant configured to react with the analyte, if present, in the bodily fluid sample after being contacted with liquid;

inserting the fluidic device containing the bodily fluid sample into a reader assembly, the fluidic device comprising an identifier corresponding to a protocol to be used with the fluidic device, the protocol including instructions to perform the assay, wherein the reader assembly is configured to receive the fluidic device inside the reader assembly;

receiving at the reader assembly a selected protocol from an external device, wherein the selected protocol is selected from a plurality of protocols in response to detecting the identifier of the fluidic device;

executing the selected protocol to perform the assay such that an actuating element causes movement of the bodily fluid sample within the fluidic device to the reaction site according to the selected protocol for reaction with the reactant contained within the reaction site after the reactant is contacted with liquid if the analyte is present, wherein the assay assembly does not yield a detectable signal that indicates the presence of the analyte; and

transmitting to the external device an indication that no detectable signal was detected.

21. The method of claim 19 or 20 , wherein the reader assembly comprises a detection assembly configured to detect the detectable signal, if generated, and a communication assembly configured to transmit to the external device the indication that the detected signal was or was not detected.

22. The method of claim 19 or 20 , wherein the fluidic device comprises a cartridge.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: GOLDEN DIAGNOSTICS TOP CORP.
To: GOLDEN DIAGNOSTICS CORP.
Reel/Frame 064264/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: LABRADOR DIAGNOSTICS LLC
To: GOLDEN DIAGNOSTICS TOP CORP.
Reel/Frame 064262/0539 →
CHANGE OF NAME Recorded Apr 7, 2020
From: THERANOS IP COMPANY LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052329/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2018
From: THERANOS, INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 045075/0310 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2017
From: THERANOS INC.
To: THERANOS IP COMPANY, LLC
Reel/Frame 044838/0909 →
SECURITY INTEREST Recorded Dec 12, 2017
From: THERANOS IP COMPANY, LLC
To: FORTRESS CREDIT CORP.
Reel/Frame 044839/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2017
From: HOLMES, ELIZABETH A.; GIBBONS, IAN; KEMP, TIMOTHY; HOWARD, JOHN; ROY, SHAUNAK
To: THERANOS, INC.
Reel/Frame 042360/0944 →
Continuity (6)
Continuation 11388823 · Mar 24, 2006
Provisional Application 60721097 · Sep 28, 2005
Provisional Application 60717192 · Sep 16, 2005
Provisional Application 60705489 · Aug 5, 2005
Provisional Application 60678801 · May 9, 2005
Related Publication 20150099311A1 · Apr 9, 2015